Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Pharmacology, Toxicology and Pharmaceutical Science
3
1%
Other
11
5%
Unknown
81
39%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 58. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 March 2026.
All research outputs
#928,858
of 34,546,575 outputs
Outputs from Lancet Oncology
#1,230
of 8,015 outputs
Outputs of similar age
#14,896
of 387,892 outputs
Outputs of similar age from Lancet Oncology
#28
of 130 outputs
Altmetric has tracked 34,546,575 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,015 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 39.4. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 387,892 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 130 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.
